tiprankstipranks
Revance Therapeutics (RVNC)
NASDAQ:RVNC

Revance Therapeutics (RVNC) Income Statement

554 Followers

Revance Therapeutics Income Statement

Last quarter (Q4 2023), Revance Therapeutics's total revenue was $69.80M, an increase of 39.82% from the same quarter last year. In Q4, Revance Therapeutics's net income was $-55.70M. See Revance Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 234.04M$ 234.04M$ 132.56M$ 77.80M$ 15.32M$ 413.00K
Cost of Revenue
$ 58.19M$ 74.36M$ 51.67M-$ 4.77M$ 0.00
Gross Profit
$ 175.85M$ 159.68M$ 80.90M$ 77.80M$ 10.56M$ 413.00K
Operating Expense
$ 525.83M$ 550.82M$ 474.52M$ -352.47M$ 283.72M$ 164.87M
Operating Income
$ -313.09M$ -316.78M$ -341.96M$ -251.55M$ -273.16M$ -164.46M
Net Non Operating Interest Income Expense
$ -19.36M$ -19.36M$ -16.47M$ -6.27M$ -10.83M$ 5.53M
Other Income Expense
$ -12.45M$ -12.45M$ -2.71M$ 361.00K$ -721.00K$ -502.00K
Pretax Income
$ -323.69M$ -323.69M$ -355.72M$ -281.31M$ -284.71M$ -159.43M
Tax Provision
$ 300.00K$ 300.00K$ 700.00K$ -246.00K$ -2.62M$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -323.99M$ -323.99M$ -356.42M$ -562.62M$ -282.09M$ -159.43M
Basic EPS
$ -3.81$ -3.83$ -4.90$ -4.17$ -4.86$ -3.67
Diluted EPS
$ -3.81$ -3.83$ -4.90$ -4.17$ -4.86$ -3.67
Basic Average Shares
$ 338.40M$ 84.60M$ 72.71M$ 67.51M$ 58.01M$ 43.46M
Diluted Average Shares
$ 338.40M$ 84.60M$ 72.71M$ 67.51M$ 58.01M$ 43.46M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 319.04M$ 625.18M$ 526.19M$ -352.47M$ 288.49M$ 164.87M
Net Income From Continuing And Discontinued Operation
$ -323.99M$ -323.99M$ -356.42M$ -281.31M$ -282.09M$ -159.43M
Normalized Income
$ -18.11M-$ -211.23M-$ -281.96M$ -159.23M
Interest Expense
----$ 15.15M$ 0.00
EBIT
$ -246.79M$ -289.19M$ -327.39M$ -275.04M$ -269.56M$ -159.43M
EBITDA
$ -241.39M$ -279.54M$ -288.54M$ -261.05M$ -259.31M$ -156.52M
Currency in USD

Revance Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis